<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:7pt Arial, sans-serif; }
 .font1 { font:8pt Arial, sans-serif; }
 .font2 { font:9pt Arial, sans-serif; }
 .font3 { font:10pt Arial, sans-serif; }
 .font4 { font:13pt Times New Roman, serif; }
 .font5 { font:19pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font5">J.P. Morgan</span></p>
<p><span class="font2" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font0" style="font-weight:bold;">07 September 2016</span></p>
<p><span class="font0" style="font-weight:bold;">Isabella Y. Zhao, CFA</span></p>
<p><span class="font0" style="font-weight:bold;">(852) 2800-8534</span></p>
<p><a href="mailto:isabella.zhao@jpmorgan.com"><span class="font0" style="font-weight:bold;">isabella.zhao@jpmorgan.com</span></a></p>
<p><span class="font4">company. The acquisition will increase the global presence of Fosun and fits right into its strategy of global expansion.</span></p>
<p><span class="font4">Gland Pharma, established in 1998, develops and manufacturers generic injectables in therapeutic areas of antibiotics, oncology and cardiology and distributes them in more than 78 countries. It is one of the largest global players in this market with revenue of $178mn in 2014 growing at a CAGR of 48% over 2010-14. The company owns 54 ANDA in the US along with another 84 ANDA in pipeline. In total its portfolio consists of 137 products. The company also has a strong R&amp;D team which has enabled it to develop a strong pipeline of drugs in the categories like high value complex generics, oncology, ophthalmic and sterile injections. Also, out of $170mn CAPEX over the last 5 years, $150mn is spent on growth assets which are yet to deliver commercial sales, hence driving future sales growth.</span></p>
<p><span class="font3" style="font-weight:bold;">Table 9: Gland pharma acquisition advantages</span></p>
<table border="1">
<tr><td colspan="6" style="vertical-align:middle;">
<p><span class="font3" style="font-weight:bold;">Advantages from Gland Pharma acquisition</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font2">Fosun Pharma has obtained FDA approval for oral formulations. The acquisition enables Fosun Pharma with both oral and Injectable platforms, Increasing market occupancy in the global formulation market</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">Gland Pharma brings stronger registration and marketing capabilities in regulated markets. The two companies may also provide support for sales In Chinese and Indian markets.</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">Fosun Pharma could transfer bi os Im liar R&amp;D capabilities to Gland Pharma to explore the biopharmaceutical market In India.</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">Fosun Pharma’s ample API resources, such as Heparin, Rocuronium Bromide, and Pemetrexed will help Gland Pharma to reduce cost lift competitiveness and raise profitability.</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">Diverse chemical drug product lines, including ANDA projects of the two companies could optimize resources In R&amp;D, International registration and technical expertise.</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">The Interactions between Gland Pharma and Fosun Pharma will accelerate the upgrading of manufacturing capabilities for global competitions.</span></p></td></tr>
</table>
<p><span class="font1">Source: Company data, J.P. Morgan Research</span></p>
<p><span class="font0" style="font-weight:bold;">14</span></p>
</body>
</html>